Product Description: C646 is a selective and competitive histone acetyltransferase p300 inhibitor with Ki of 400 nM, and is less potent for other acetyltransferases[1].
Applications: Cancer-Kinase/protease
Formula: C24H19N3O6
References: [1]Bowers EM, et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol. 2010 May 28;17(5):471-82./[2]Oike T, et al. C646, a selective small molecule inhibitor of histone acetyltransferase p300, radiosensitizes lung cancer cells by enhancing mitotic catastrophe. Radiother Oncol. 2014 May;111(2):222-7./[3]Zheng WW, et al. EDAG positively regulates erythroid differentiation and modifies GATA1 acetylation through recruiting p300. Stem Cells. 2014 Aug;32(8):2278-89./[4]Zhen Fan, et al. Type 2 diabetes-induced overactivation of P300 contributes to skeletal muscle atrophy by inhibiting autophagic flux. Life Sci. 2020 Aug 10;258:118243.
CAS Number: 328968-36-1
Molecular Weight: 445.42
Compound Purity: 99.78
Research Area: Cancer
Solubility: DMSO : 13.89 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Apoptosis;Autophagy;Epigenetic Reader Domain;Histone Acetyltransferase
Deutsch
English
